Should positive phase III clinical trial data be required before proton beam therapy is more widely adopted? No.
about
A Review of Radiotherapy-Induced Late Effects Research after Advanced Technology TreatmentsGlioblastoma multiforme: emerging treatments and stratification markers beyond new drugsFound in translation: Integrating laboratory and clinical oncology researchRecommendations for the referral of patients for proton-beam therapy, an Alberta Health Services report: a model for Canada?Heidelberg Ion Therapy Center (HIT): Initial clinical experience in the first 80 patients.Clival chordoma: a single-centre outcome analysis.Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: the CLEOPATRA trialVision 20/20: proton therapy.When to wait for more evidence? Real options analysis in proton therapy.Proton beam therapy: the next disruptive innovation in healthcare?Proton beam stereotactic radiosurgery for pediatric cerebral arteriovenous malformations.Maximum proton kinetic energy and patient-generated neutron fluence considerations in proton beam arc delivery radiation therapy.Radiation therapy for pediatric central nervous system tumors.Proton radiation in the management of localized cancer.Real-time 4-D radiotherapy for lung cancer.Clinical evidence of particle beam therapy (proton).Particle therapy for noncancer diseases.The use of proton-beam therapy in the treatment of non-small-cell lung cancer.Charged-particle therapy in cancer: clinical uses and future perspectives.Proton therapy in paediatric oncology: an Irish perspective.The role of medical physicists in clinical trials: More than quality assurance.Online advertising and marketing claims by providers of proton beam therapy: are they guideline-based?
P2860
Q26767255-20D0E54C-CCB2-46A1-BE4F-18CD6540FBC2Q28082603-9F221505-7AF5-408E-B4EE-AD36444B4C7EQ28744471-234D0041-65D2-4813-8E62-28326A5D8C4EQ30428790-6DD807BE-0600-4DB4-88CA-952A91DAD080Q33273911-08C41163-95C7-4F88-9F63-41FB535F0A20Q33276496-A2D9998B-6BDB-4F2E-815A-547C177ECF91Q33684972-8A452275-27BC-41F7-A2B5-48A5CBD1F2C7Q34963839-0B37746D-373C-428D-B3C1-C3CAE3127AA7Q35642383-07EB79DC-827C-415A-ADD5-2427609291FBQ35750680-83B37BCD-ED4C-43E4-BF1C-17FEEB2A8C62Q36877064-ABE02499-7329-4DF3-A5AE-E09FDC3AB465Q37330433-34D5767C-7FDF-489B-8F3C-BC4A3CB801B0Q37617841-75263A08-0072-4DDA-AB57-D23B14FB77CEQ37705368-B7B02AD2-8D67-43A2-BEF0-E77CF575BD05Q37939960-5B713269-1D45-4D92-BE0D-BFE176B32FE9Q37994609-7E40F409-B642-4B80-BFB4-418809971A7CQ38000635-A49620DD-C26A-4EF3-B290-4D927B3A0366Q38088273-C3A71980-FEB9-4E15-B5BE-EFF8F2BF5316Q38746213-6D6846C3-85D2-4729-8B73-6D5EE637A8ACQ38981759-5B6263F0-188A-4713-8DFE-11CF291C5A9BQ42625823-335C87BD-82CC-4433-B1EE-53A6441E9212Q55384451-CB4B99E1-0525-4CC1-B734-036170D1B767
P2860
Should positive phase III clinical trial data be required before proton beam therapy is more widely adopted? No.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Should positive phase III clin ...... py is more widely adopted? No.
@ast
Should positive phase III clin ...... py is more widely adopted? No.
@en
type
label
Should positive phase III clin ...... py is more widely adopted? No.
@ast
Should positive phase III clin ...... py is more widely adopted? No.
@en
prefLabel
Should positive phase III clin ...... py is more widely adopted? No.
@ast
Should positive phase III clin ...... py is more widely adopted? No.
@en
P2093
P1476
Should positive phase III clin ...... py is more widely adopted? No.
@en
P2093
Alexei Trofimov
Benjamin Clasie
Hanne Kooy
Harald Paganetti
Herman Suit
Jay Loeffler
John Munzenrider
Jonathan Farr
Sairos Safai
Thomas DeLaney
P304
P356
10.1016/J.RADONC.2007.12.024
P577
2008-01-30T00:00:00Z